|
|
NEWS
RECALLS
COMPLAINT FORM
SCAM ALERTS
RESOURCES
Small Claims Guide Class Actions Lemon Laws FAQ Newsletters |
|
| Automotive Education Employment Electronics Family Finance Health Homeowners Insurance Pets Shopping Travel |
|
|
|
![]() |
Bill Banning Drug "Pay-For-Delay" Gets HearingLegislation would prevent Big Pharma from delaying generic alternatives |
||||||||
|
June 4, 2009
The bill — the Protecting Consumer Access to Generic Drugs Act of 2009, H.R. 1706 — which would prohibit these anticompetitive settlements in which a drug company challenging a patent agrees to delay its challenge in return for a settlement with the company that holds the patent. Supporters of the legislation say it can provide a comprehensive solution to a problem that is prevalent, extremely costly, and subverts the goals of the Hatch-Waxman Act, which was designed to prevent weak patents from obstructing lower-cost generic drug competition. Richard A. Feinstein, Bureau of Competition Director for the Food and Drug Administration, appeared before the House Judiciary Committee's Subcommittee on Courts and Competition Policy in support of the measure. He testified that anticompetitive patent settlements in the U.S. pharmaceutical industry delay consumer access to lower-cost generic drugs, and impose "enormous costs" on consumers; employers; federal, state and local governments; and the U.S. health care system. Congressional action to prohibit these "pay-for-delay" settlements between brand-name drug manufacturers and their generic competitors is "both appropriate and timely," he said, and would help contain spiraling health care costs. Without a law in place, the FTC has sought to use antitrust enforcement to stop so-called "pay-for-delay" agreements. "Since 2005, court decisions have taken a lenient approach to such agreements in drug patent settlements," Feinstein testified. As a result, it has become increasingly difficult to bring antitrust cases to stop pay-for-delay tactics, and such agreements have become a common industry strategy. The implications are troubling, Feinstein said, because the increased costs resulting from anticompetitive agreements that delay generic competition harm all those who pay for prescription drugs. Feinstein said the FTC continues to use its enforcement authority to challenge pay-for-delay settlements, bringing two new cases in the past 16 months. Despite the Commission's ongoing antitrust enforcement efforts, however, the appellate court decisions upholding the legality of pay-for-delay settlements "have prompted a resurgence in settlements in which parties settle with a payment to the generic company and an agreement by the generic company not to market its product," Feinstein said. Report Your Experience
|
||||||||
Back to the top | |
|||||||||
Advertisement
|
|
Custom Search
|
||||
|
AUTOMOTIVE Dealers Manufacturers Service Extended Warranties Lemon Laws Recalls Tires Transporters FAMILY Aging Children, Parenting Recalls Dating Education Entertainment Pets Weddings |
FINANCE Annuities Banks Credit Cards Debt Collection Debt Counseling Insurance Investing Loans Mortgages Payday Loans Student Loans Tax Prep HEALTH Doctors Drugs, Pharmacies Health Clubs Hearing Care Hospitals Nursing Homes Nutrition, Diets Vision Care Weight Loss |
HOUSE & HOME Appliances Cookware Furniture Home Improvements Lawn & Garden Movers Pools & Spas Realtors, Rental Agents Recalls Utilities ELECTRONICS Cable TV/DBS Cameras Cell Phones Computers Home Electronics Internet Access Local Phone Service Long Distance VoIP |
SHOPPING Delivery Services In-Home Online Retail Stores Sporting Goods Supermarkets Telemarketers TRAVEL Airlines Bus Lines Car Rental Cruises Hotels Travel Agents Trains RESOURCES Class Actions Complaint Form Small Claims Guide Lemon Laws |
CONSUMER NEWS Latest News Automotive Telecom Financial Health Homeowners Scams Seniors Travel More ... RECALLS Automotive Children's Products Drugs Food Household Products Sporting Goods ABOUT US FAQ Privacy Policy Advertise With Us Newsroom Syndication Terms of Use |
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2010 ConsumerAffairs.com Inc. All Rights Reserved. The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission. |
|